The Cooper Companies, Inc.

(NASDAQ Global Select)
Back to all articles
Bearish -60

Cooper Companies (COO) Stock Plunges 15% on Scrapped Sale and Revenue Miss

AI-generated analysis

πŸ“‰ Cooper Companies (COO) shares tumbled more than 15% in premarket trading after the firm announced disappointing quarterly results and decided to retain its CooperSurgical division.

πŸ’° Third-quarter revenue reached $1.07 billion, falling short of Wall Street's $1.10 billion projection due to an intentional drawdown of U.S. distribution channel inventory.

πŸ“‰ Management reduced full-year adjusted earnings per share guidance to $4.51-$4.55 and annual revenue projections to $4.23-$4.25 billion.

πŸ‘οΈ The CooperVision segment reported quarterly revenue of $717 million, down from $723.5 million in the previous quarter due to inventory normalization.

πŸ’Έ Despite missing revenue, the company exceeded adjusted EPS estimates at $1.15 versus the consensus of $1.12.

πŸ”„ The board unanimously determined to keep the CooperSurgical business unit, eliminating investor hopes for a divestiture that could have created a focused contact lens enterprise.

πŸ’° Cooper expanded its share buyback authorization from $2 billion to $3 billion following the earnings announcement.

πŸ† Cooper maintains the position of the second-largest contact lens producer worldwide, trailing only Johnson & Johnson's Acuvue brand.

πŸ“… Management indicated that inventory challenges impacting the third quarter will persist through the final quarter of fiscal year 2026.

πŸ‘” KeyBanc analyst Brett Fishbin maintains a Sector Weight rating on the shares following the strategic review conclusion.

Bullish Signals
  • Cooper Companies exceeded adjusted earnings per share projections, reporting $1.15 versus the consensus estimate of $1.12.
  • The company expanded its share buyback authorization from $2 billion to $3 billion, signaling confidence in capital allocation.
  • Cooper maintains the position of the second-largest contact lens producer worldwide, trailing only Johnson & Johnson's Acuvue brand.
Risk Factors
  • Shares plummeted over 15% after the company decided to retain its CooperSurgical division, dashing investor expectations of a potential divestiture.
  • Third-quarter revenue of $1.07 billion fell short of Wall Street's $1.10 billion projection due to deliberate inventory drawdowns in the United States.
  • Management reduced its full-year adjusted earnings per share outlook to $4.51-$4.55, down from the previous range of $4.58-$4.66.
  • Annual revenue projections were lowered to $4.23-$4.25 billion from the earlier forecast of $4.29-$4.32 billion.
  • The CooperVision segment reported quarterly revenue of $717 million, down from $723.5 million in the previous quarter due to inventory normalization.
  • Management indicated that inventory challenges impacting the third quarter will persist through the fourth quarter.
Full Analysis
Cooper Companies (COO) shares plummeted over 15% in premarket trading after the medical device manufacturer announced disappointing third-quarter results and a strategic reversal. Investors had anticipated a potential divestiture of its CooperSurgical division, viewing it as a catalyst for a focused contact lens business or acquisition. However, the company's board unanimously decided to retain the women's healthcare unit following a strategic assessment, dashing market expectations. Financially, the company missed third-quarter revenue guidance, reporting $1.07 billion against Wall Street's expectation of $1.10 billion. While adjusted earnings per share beat estimates at $1.15 versus $1.12, management reduced its full-year outlook for both metrics. The revised fiscal year adjusted EPS guidance stands between $4.51 and $4.55, down from the previous range of $4.58 to $4.66. The revenue shortfall was primarily driven by a deliberate inventory drawdown in the United States for its CooperVision contact lens segment, which generated $717 million compared to $723.5 million in the prior quarter. Management indicated that these inventory challenges will persist through the fourth quarter, with projected Q4 revenue between $1.06 and $1.08 billion. Additionally, the company expanded its share buyback authorization from $2 billion to $3 billion.